Overview

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of ombitasvir/paritaprevir/ ritonavir and dasabuvir administered for 8 weeks in treatment-naïve participants with genotype 1b (GT1b) hepatitis C virus (HCV).

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Treatments:

Ritonavir